Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Loomba

Showing results (141-150 of 750) with videos related to

Pageof 75
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 18, 2020
Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018Donghee Kim, George Cholankeril, Rohit Loomba, et al.
Hepatology (Baltimore, Md.)|March 30, 2026
Noninvasive surrogate endpoints of adverse outcomes, disease progression, and treatment efficacy in Metabolic Dysfunction-Associated Steatohepatitis (MASH)Arun J Sanyal, Manal F Abdelmalek, Rohit Loomba
Current Diabetes Reports|March 14, 2026
Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 DiabetesKonstantinos Malandris, Konstantinos Charalampidis, Rohit Loomba, et al.
The New England Journal of Medicine|October 16, 2024
Two Trials of Therapeutics for MASH with Liver Fibrosis. ReplyRohit Loomba, Mark L Hartman, Arun J Sanyal
Journal of Cardiovascular Development and Disease|February 9, 2018
Is an Appreciation of Isomerism the Key to Unlocking the Mysteries of the Cardiac Findings in Heterotaxy?Robert H Anderson, Diane E Spicer, Rohit Loomba
Hepatology Communications|September 9, 2021
What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?Naim Alkhouri, Monica Tincopa, Rohit Loomba, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 12, 2021
Treatment Candidacy for Pharmacologic Therapies for NASHIan A Rowe, Vincent Wai-Sun Wong, Rohit Loomba
Journal of Hepatology|April 15, 2023
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASHFrank Tacke, Tobias Puengel, Rohit Loomba, et al.
Journal of Lipid Research|November 19, 2014
Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitisRohit Loomba, Oswald Quehenberger, Aaron Armando, et al.
Alimentary Pharmacology & Therapeutics|May 14, 2025
Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLDMaryam Zafer, Federica Tavaglione, Manuel Romero-Gómez, et al.
Pageof 75

Showing results (141-150 of 750) with videos related to

Sort By:
Pageof 75
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 18, 2020
Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018Donghee Kim, George Cholankeril, Rohit Loomba, et al.
Hepatology (Baltimore, Md.)|March 30, 2026
Noninvasive surrogate endpoints of adverse outcomes, disease progression, and treatment efficacy in Metabolic Dysfunction-Associated Steatohepatitis (MASH)Arun J Sanyal, Manal F Abdelmalek, Rohit Loomba
Current Diabetes Reports|March 14, 2026
Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 DiabetesKonstantinos Malandris, Konstantinos Charalampidis, Rohit Loomba, et al.
The New England Journal of Medicine|October 16, 2024
Two Trials of Therapeutics for MASH with Liver Fibrosis. ReplyRohit Loomba, Mark L Hartman, Arun J Sanyal
Journal of Cardiovascular Development and Disease|February 9, 2018
Is an Appreciation of Isomerism the Key to Unlocking the Mysteries of the Cardiac Findings in Heterotaxy?Robert H Anderson, Diane E Spicer, Rohit Loomba
Hepatology Communications|September 9, 2021
What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?Naim Alkhouri, Monica Tincopa, Rohit Loomba, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 12, 2021
Treatment Candidacy for Pharmacologic Therapies for NASHIan A Rowe, Vincent Wai-Sun Wong, Rohit Loomba
Journal of Hepatology|April 15, 2023
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASHFrank Tacke, Tobias Puengel, Rohit Loomba, et al.
Journal of Lipid Research|November 19, 2014
Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitisRohit Loomba, Oswald Quehenberger, Aaron Armando, et al.
Alimentary Pharmacology & Therapeutics|May 14, 2025
Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLDMaryam Zafer, Federica Tavaglione, Manuel Romero-Gómez, et al.
Pageof 75